Metastatic #MetaplasticBreastCancer DART Trial NCT02834013

Ipilimumab + Nivolumab

Phase II
3/17 (2 Spindle, 1 Chondromyxoid, low tumor mutational burden, microsatellite stable, 2/3 PD-L1-low/neg🧐) achieved durable (28/33/34 mo) Objective Response

#CCR_AACR 2022
aacrjournals.org/clincancerre...